Drug Trial Radar · NCT06988553
A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jun 17, 2025
Primary completion
Nov 28, 2025
Study completion Nov 28, 2025
Sponsor
- Lead sponsor
- EccogeneIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese participants with overweight/obesity with or without T2DM.
Conditions
- Obesity or Overweight
- Type 2 Diabetes
Interventions
AZD5004Drug
AZD5004 will be administered as an oral tablet once daily.
PlaceboDrug
Placebo will be administered as an oral tablet once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse event leading to the discontinuation of study intervention (DAEs), death, and Adverse events of special interest (AESIs)Time frame: From baseline to week 16.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
The Fourth Affiliated Hospital of Harbin Medical University
Ha’erbin, China
The Second People's Hospital of Hefei
Hefei, China
Jinan Central Hospital
Jinan, China
Shanghai Pudong New District People's Hospital
Shanghai, China
General Hospital of Tianjin Medical University
Tianjin, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.